Fresh on the heels of launching Oncotype DX for colorectal cancer recurrence in stage II patients last week, Genomic Health is already working on expanding the indication of the test into later stages of the disease as well as into renal cancer, ductal carcinoma in situ, and prostate cancer.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.